Regulatory Aspects Towards Approval of Nanomedicine

Nanomedicines have been in the forefront of pharmaceutical research in the last decades, creating new challenges for research community, industry, and regulators. There is a strong demand for the fast development of scientific and technological tools to address unmet medical needs, thus improving human health care and life quality. Tremendous advances in the biomaterials and nanotechnology fields have prompted their use as promising tools to overcome important drawbacks, mostly associated to the non-specific effects of conventional therapeutic approaches. However, the wide range of application of nanomedicines demands a profound knowledge and characterization of these complex products. Their properties need to be extensively understood to avoid unpredicted effects on patients, such as potential immune reactivity. Research policy and alliances have been bringing together scientists, regulators, industry, and, more frequently in recent years, patient representatives and patient advocacy institutions. In order to successfully enhance the development of new technologies, improved strategies for research-based corporate organizations, more integrated research tools dealing with appropriate translational requirements aiming at clinical development, and proactive regulatory policies are essential in the near future. This review focuses on the most important aspects currently recognized as key factors for the regulation of nanomedicines, discussing the efforts under development by industry and regulatory agencies to promote their translation into the market.

  • Nanomedicine: Prospects, Risks and Regulatory Issues
  • Current , Future Applications and Regulatory challenges
  • Current , Future Applications and Regulatory challenges
  • Research Policy and Alliances
  • Regulatory Policies
  • Regulation of Nanomedicines

Related Conference of Regulatory Aspects Towards Approval of Nanomedicine

Sep 25-26, 2017

12th Annual
Pharma Middle East Congress

Dubai, UAE
October 02-03, 2017

9th Annual Pharmaceutical Chemical Analysis Congress

Vienna, Austria
October 05-06, 2017 Park Inn by Radisson London Heathrow,

5th International Conference and Exhibition on Pain Research and Management

London, UK
October 16-17, 2017

16th Annual Medicinal & Pharmaceutical Sciences Congress

Seoul, South Korea
October 16-18, 2017
(10 Plenary Forums - 1 Event)

4th International Conference on Past and Present Research Systems of Green Chemistry

Atlanta, Georgia, USA
October 18-19, 2017

6th Global Congress on Mass Spectrometry

Osaka, Japan
October 19-20, 2017

9th Annual Congress on Drug Design & Drug Formulation

Seoul, South Korea
October 19-20, 2017

4th International Conference and Exhibition on Pain Medicine

(10 Plenary Forums - 1 Event)
San Francisco, California, USA
October 30-November 01, 2017
A B2B Networking & Global Knowledge Exchange Forum

Annual Congress on Emerging Orphan Drugs and  Rare Diseases

San Antonio, Texas, USA
April 20-21, 2018

4th International Conference on Antibiotics

Las Vegas, Nevada, USA
April 26-27, 2018

11th European Biosimilars Congress

Rome, Italy
May 07-09, 2018

10th Annual European Pharma Congress

Frankfurt, Germany
June 18-19, 2018

9th Global Experts Meeting on Neuropharmacology

Paris, France
June 20-22, 2018

7th World Congress on Mass Spectrometry

Rome, Italy
July 09-10, 2018

12th Global
Pharmacovigilance & Clinical Trials Summit

Sydney, Australia
July 16-18, 2018

15th Asia-Pacific Pharma Congress

Melbourne, Australia
Jul 30-Aug 01, 2018

10th World Congress on Pharmacology

Barcelona, Spain
September 13-14, 2018

8th World Congress on Chromatography

Prague, Czech Republic
September 24-25, 2018

7th International Conference on Clinical Trials

Chicago, USA
(10 Plenary Forums - 1 Event)

Regulatory Aspects Towards Approval of Nanomedicine Conference Speakers

Recommended Sessions

Related Journals

Are you interested in